| Anderson, Craig |
ASPIRING, NCT04522102: Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe ()-Pilot Phase |
|
|
| Active, not recruiting | 3 | 80 | RoW | Start antiplatelet monotherapy | The George Institute for Global Health, China, University of Edinburgh, Huashan Hospital, The University of Western Australia | Intracerebral Hemorrhage | 10/23 | 10/23 | | |
| Completed | 3 | 2425 | RoW | urapidil, Intensive BP lowing | The George Institute for Global Health, China, Shanghai East Hospital, China, First Affiliated Hospital of Chengdu Medical College, China, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, China | Stroke, Acute, Cerebrovascular Disorders | 11/23 | 11/23 | | |
ACT-WHEN, NCT06320431: ACT-GLOBAL THROMBOLYSIS (-001) Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632 |
|
|
| Recruiting | 3 | 4000 | Canada, RoW | Tenecteplase, TNKase, Metalyse | University of Calgary, The George Institute for Global Health, Australia | Acute Ischemic Stroke AIS, Stroke Acute, Stroke, Acute, Stroke Ischemic | 09/30 | 12/30 | | |
| Recruiting | 3 | 20000 | Canada, RoW | Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase, Conservative Blood Pressure Control, Moderate Blood Pressure Control, Intensive Blood Pressure Control, Placebo, NoNO-42, No deferoxamine mesylate and no colchicine, Deferoxamine mesylate only, Colchicine only, Both deferoxamine mesylate and colchicine | The George Institute, University of Calgary, Berry Consultants | Stroke | 09/34 | 09/34 | | |
| Recruiting | 3 | 1600 | Europe, RoW | telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg, Triple Pill, Placebo | The George Institute, The University of New South Wales | Intracerebral Haemorrhage (ICH), Hypertension | 06/25 | 06/25 | | |
NCT05066620: Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial |
|
|
| Not yet recruiting | 3 | 1504 | RoW | Chinese herbal medicine FYTF-919, Chinese herbal medicine | Guangzhou University of Traditional Chinese Medicine, The George Institute | Intracerebral Hemorrhage | 12/24 | 01/25 | | |
| Recruiting | 3 | 400 | RoW | Atorvastatin, Standard Care | The George Institute, University of Sydney, Monash University, The Alfred, Universidad del Desarrollo, Chinese University of Hong Kong, Clinica Alemana de Santiago | Neurocognitive Impairment, Mild | 12/24 | 12/24 | | |
EAST, NCT06773364: Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial |
|
|
| Not yet recruiting | 3 | 2423 | NA | Levetiracetam, Guide-recommended management, The lying flat (0°) head position, The sitting-up (≥30°) head position | Shanghai East Hospital | Suspected Stroke | 12/28 | 12/29 | | |
| Suspended | 2 | 80 | RoW | TBO-309 | The George Institute, Heart Research Institute | Acute Ischemic Stroke | 02/26 | 05/26 | | |
NCT05483595: An Examination of Blinding for Chinese Herbal Oral Liquid and Matched Placebo |
|
|
| Completed | N/A | 48 | RoW | Chinese herbal medicine FYTF-919, Zhong Feng Xing Nao (ZFXN) prescription | Guangzhou University of Traditional Chinese Medicine | Placebo Evaluate | 06/23 | 06/23 | | |
NCT06427096: Effect of Healthy Family Program on Population Blood Pressure |
|
|
| Recruiting | N/A | 8000 | RoW | Multifaceted intervention | Heart Health Research Center | Blood Pressure | 02/25 | 08/25 | | |
ENCHANTED3/MT, NCT06352619: Third Enhanced Control of Hypertension and Thrombectomy Stroke Domain Within ACT-GLOBAL Adaptive Platform Trial |
|
|
| Recruiting | N/A | 2000 | Canada, RoW | Conservative SBP Control, Moderate SBP Control, Intensive SBP Control | The George Institute, University of Calgary, Changhai Hospital | Ischemic Stroke, Acute | 05/26 | 05/26 | | |
| Recruiting | N/A | 382 | RoW | Mechanical thrombectomy | The George Institute for Global Health, China, Changhai Hospital | Acute Ischemic Stroke | 10/24 | 01/25 | | |
| Recruiting | N/A | 7200 | Europe, US, RoW | Low-intensity monitoring strategy, Guideline recommended standard monitoring | Craig Anderson, Genentech, Inc., Johns Hopkins University, The George Institute for Global Health, Australia | Acute Ischemic Stroke Patients Receiving Reperfusion Therapy | 11/24 | 03/25 | | |
| Recruiting | N/A | 1675 | RoW | Intensive BP Control, Control of home SBP to a target of 120mmHg, Standard BP Control, Control of home SBP to a target of 135mmHg | Beijing Anzhen Hospital, Heart Health Research Center, The George Institute for Global Health, China, The George Institute for Global Health, Australia, Fukuoka University | Atrial Fibrillation, Hypertension | 06/24 | 12/25 | | |
NCT04157231: Essential Acute Stroke Care in Low Resource Settings: a Pilot studY |
|
|
| Not yet recruiting | N/A | 300 | RoW | Acute stroke care Intervention arm | The George Institute, World Heart Federation | Acute Stroke | 10/25 | 11/25 | | |
| Ang, Timothy |
INTERACT5, NCT06763055: The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL |
|
|
| Recruiting | 3 | 2000 | RoW | Colchicine 0.5 mg, Deferoxamine Mesylate, Yes DX, Control (Standard treatment) | The George Institute, University of Calgary | Intracerebral Hemorrhage, Spontaneous Intracerebral Hemorrhage, Supratentorial Intracerebral Haemorrhage, Acute Intracerebral Haemorrhage, Acute Stroke | 01/28 | 01/29 | | |
| Suspended | 2 | 80 | RoW | TBO-309 | The George Institute, Heart Research Institute | Acute Ischemic Stroke | 02/26 | 05/26 | | |
